Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Ineye Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610084, China.
Comput Math Methods Med. 2022 Dec 22;2022:7316794. doi: 10.1155/2022/7316794. eCollection 2022.
Dry eye disease (DED) is a multifactorial disease of the ocular surface, which affects the quality of life and work efficiency of affected patients. The traditional Chinese medicine formula Qiju Dihuang Pill (QJDHP) has a good therapeutic effect on DED. However, the pharmacological mechanism is not clear.
To explore the mechanism of QJDHP in the treatment of DED based on network pharmacology.
The active components in QJDHP were screened in Traditional Chinese Medicine Systems Pharmacology (TCMSP), and putative molecular targets of QJDHP were identified using the SwissTargetPrediction database. DED-related targets were screened by GeneCards and OMIM. We established protein-protein interaction (PPI) and core targets and corresponding active compound network by Cytoscape to identify the core targets and main compounds of QJDHP against DED. DAVID database was utilized for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Molecular docking was used to evaluate the binding activity between key active compounds and core targets.
The results of network pharmacology showed that 253 targets of QJDHP were related to DED. PPI network analysis showed the 18 core targets. The binding affinity of docking results ranged from -5.7 to -9.3 kcal/mol, indicating a good docking effect. The results of GO enrichment analysis showed that the mechanism of QJDHP in the treatment of DED mainly involved biological processes such as apoptosis, oxidative stress, response to estrogen, angiogenesis, and the regulation of transcription factors. KEGG analysis showed that QJDHP may be regulated by the TNF signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway, and estrogen signaling pathway in the treatment of DED.
In this study, we demonstrated the multicomponent, multitarget, and multichannel action mechanism of QJDHP in the treatment of DED and provided a foundation for further drug development research.
干眼症(DED)是一种眼表多因素疾病,影响患者的生活质量和工作效率。中药方剂杞菊地黄丸(QJDHP)对 DED 有较好的治疗效果,但作用机制尚不清楚。
基于网络药理学探讨 QJDHP 治疗 DED 的作用机制。
在中药系统药理学数据库与分析平台(TCMSP)中筛选 QJDHP 的活性成分,利用瑞士药物靶标预测数据库(SwissTargetPrediction)预测 QJDHP 的潜在作用靶点。从基因数据库(GeneCards)和在线孟德尔遗传数据库(OMIM)筛选 DED 相关靶点。采用 Cytoscape 软件构建蛋白质-蛋白质相互作用(PPI)网络和核心靶点及对应活性化合物网络,识别 QJDHP 治疗 DED 的核心靶点和主要化合物。利用 DAVID 数据库进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。采用分子对接技术评价关键活性化合物与核心靶点的结合活性。
网络药理学结果显示,QJDHP 治疗 DED 的相关靶点有 253 个。PPI 网络分析显示,有 18 个核心靶点。分子对接结果显示,结合自由能范围为-5.7~-9.3 kcal/mol,表明对接效果较好。GO 富集分析结果表明,QJDHP 治疗 DED 的作用机制主要涉及细胞凋亡、氧化应激、雌激素反应、血管生成和转录因子调控等生物学过程。KEGG 通路分析表明,QJDHP 可能通过 TNF 信号通路、Toll 样受体信号通路、MAPK 信号通路和雌激素信号通路等途径调节 DED。
本研究从多成分、多靶点、多途径阐释了 QJDHP 治疗 DED 的作用机制,为进一步的药物研发研究提供了依据。